Connect Biopharma Holdings Ltd Asset Resilience Ratio
Connect Biopharma Holdings Ltd asset resilience ratio. Connect Biopharma Holdings Ltd (CNTB) has an Asset Resilience Ratio of 10.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CNTB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Connect Biopharma Holdings Ltd (2018–2025)
Asset resilience ratio of Connect Biopharma Holdings Ltd from 2018 to 2025. This chart shows how Connect Biopharma Holdings Ltd's Asset Resilience Ratio has changed over time. Read Connect Biopharma Holdings Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Connect Biopharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Connect Biopharma Holdings Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.47 Million | 10.28% |
| Total Liquid Assets | $4.47 Million | 10.28% |
Asset Resilience Insights
- Moderate Liquidity: Connect Biopharma Holdings Ltd has 10.28% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Connect Biopharma Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Connect Biopharma Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Connect Biopharma Holdings Ltd Asset Resilience Ratio by Year (2018–2025)
Connect Biopharma Holdings Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Connect Biopharma Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.69% | $6.00 Million | $56.08 Million | -4.59pp |
| 2024-12-31 | 15.28% | $15.48 Million | $101.28 Million | +5.36pp |
| 2023-12-31 | 9.92% | $12.64 Million | $127.38 Million | -32.26pp |
| 2022-12-31 | 42.18% | $73.41 Million | $174.01 Million | +42.18pp |
| 2021-12-31 | 0.00% | $677.10 | $291.05 Million | -1.20pp |
| 2020-12-31 | 1.20% | $306.41K | $25.44 Million | -7.02pp |
| 2019-12-31 | 8.22% | $635.15K | $7.73 Million | +7.69pp |
| 2018-12-31 | 0.54% | $371.01K | $69.29 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.